The botanical extract market may be on the verge of another major branded ingredient success story. Following the global rise of KSM 66 Ashwagandha, its developer Ixoreal Biomed has introduced SRI 81 Shatavari, targeting the growing women’s health segment.
A Strategic Move Into Women’s Health
Expanding Beyond Adaptogens
While KSM 66 established a strong position in stress, sports, and cognitive categories, SRI 81 Shatavari focuses on female-specific applications. Shatavari, derived from Asparagus racemosus, has a long history in Ayurvedic practice, primarily associated with hormonal balance and reproductive health.
Standardization as a Differentiator
The key commercial strategy mirrors the KSM 66 approach
- Full spectrum extract positioning
- Clinically backed standardization
- Strong branding and IP protection
Market Potential and Positioning
Timing Aligns With Demand Trends
The women’s health supplement category continues to expand across
- Hormonal balance
- Menopause support
- Fertility and wellness
SRI 81 enters a space where demand for clinically validated botanicals is increasing, but branded dominance remains limited compared to adaptogens.
Replicating the KSM 66 Playbook
KSM 66 succeeded through a combination of clinical backing, supply chain control, and consistent branding. SRI 81 appears to follow the same model, suggesting a deliberate attempt to create a category-defining ingredient.
Industry Implications
For product developers and manufacturers, SRI 81 represents a potential early-entry opportunity into a scalable branded ingredient. If clinical validation and market education align, it could establish itself as a leading reference ingredient in women’s health formulations.
